| Today’s Big NewsMar 4, 2025 |
|
The Ohio Discovery Corridor, a leading innovation ecosystem in the Midwest, is your place to foster innovation with collaboration. Join our brightest minds in shaping the future. Explore the corridor. .png)
|
|
| By Gabrielle Masson Acelyrin consulted with independent advisors and came to the conclusion that the unsolicited interest from Tang Capital Partners-owned Concentra was “not reasonably expected to result in a superior proposal to the planned merger with Alumis." |
|
|
|
By James Waldron Up to 60 new life sciences companies are set to benefit from 1.2 billion euros ($1.68 billion) that Sofinnova Partners has raked in over the past year, the European venture capital firm has announced. |
By James Waldron Atara Biotherapeutics is halving its head count as it navigates the fallout from the FDA’s move to halt on all of the allogeneic T-cell company’s attempts to launch fresh clinical trials. |
By Darren Incorvaia Deal-happy Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a licensing pact with Japanese biotech Kyorin potentially worth hundreds of millions of dollars. |
|
Tuesday, March 11, 2025 | 11am ET / 8am PT In the world of clinical trials, where precision and compliance are critical, the role of technology is more important than ever. Join us to learn how to harness the latest innovations for driving efficiencies and more streamlined experiences for patients. Register now to take a deep dive into the most pressing challenges in clinical trials today! 
|
|
By Gabrielle Masson Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. |
By James Waldron While PepGen works to persuade the FDA to let it launch a phase 2 trial of its Duchenne muscular dystrophy therapy in the U.S., the biotech has decided to pause the U.K. arm of the study. |
By Gabrielle Masson,Darren Incorvaia The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs. |
By Darren Incorvaia A one-time injection of a novel gene therapy was able to save mice and a newborn calf from succumbing to maple syrup urine disease, suggesting the treatment could one day be used to treat patients with the rare genetic disorder. |
By Gabrielle Masson Pliant Therapeutics has discontinued a phase 2b/3 trial after recording at least a 7% higher rate of adverse events tied to idiopathic pulmonary fibrosis (IPF) in the treatment arms compared to placebo. |
By Fraiser Kansteiner Pfizer’s local manufacturing setup is already well positioned in the U.S., and the New York-based drugmaker could bring additional resources into the country if pharma import tariffs proposed by President Donald Trump take effect, the company's CEO, Albert Bourla, Ph.D., said Monday. |
By Conor Hale The KidneyVault is more than a simple ice chest. It pumps a cooled, specialized solution through the organ to help preserve it on the way to surgery. |
By Angus Liu AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer, the partners said on Monday. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we hear from Steven McCarroll, Ph.D., whose research team at the Broad Institute of MIT and Harvard recently uncovered new insights into the cause of Huntington's disease. |
|
|---|
|
|
|
Thursday, March 20, 2025 | 11am ET / 8am PT AI is no longer a novelty—it's an expectation. As stakeholders demand evidence of real-world impact, the focus is shifting from the tools themselves to the tangible results they deliver. Join us to explore how predictive sales intelligence and omnichannel strategies are transforming HCP engagement. Register now. 
|
|
Whitepaper Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
Whitepaper Develop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| Submissions Open Early August |
|
|
| |
|
